Brainstorm Cell Therapeutics Inc (New York, NY) will host a phone call on June 7th at 8:15 AM EDT to provide interested parties an opportunity to engage with the company regarding new “right-to-try” legislation. The new bill was signed into law by President Donald Trump on May 30, 2018. This legislation gives patients who are terminally ill the right to try experimental medications that are not yet approved by the Food and Drug Administration (FDA). The legislation is intended to give access to investigational medicine to patients who have exhausted all other treatment options and do not meet the clinical trial criteria.
During the signing of the bill, President Trump cited the case of Mtthew Bellina, a patient with amyotrophic lateral sclerosis (ALS) who had been seeking access to NurOwn investigational therapy, which is a stem cell treatment for ALS produced by Brainstorm Cell Therapeutics. Mr. Bellini had planned to travel overseas to receive treatment with NurOwn, and the President stated clearly that patients will now be able to seek treatment in the US without having the burden of overseas travel.
President and CEO of BrainStorm, Chaim Lebovits, was present during the bill signing to demonstrate the company’s commitment to the ALS community. He later stated, "Since the signing of the “right-to-try’ bill, we have had numerous enquiries from patients, patient advocates, and physicians who want to voice their opinions as we establish our RTT policy. . . (W)e are happy to provide interested groups this opportunity to engage directly with us. We recognize the sense of urgency of ALS patients. . . and are evaluating ways to provide access outside of our phase 3 trial. At the same time, we remain fully focused on completing our Phase 3 trial of NurOwn as rapidly as possible."Next Story